We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.72B
AUM Growth
-$344M
Cap. Flow
-$310M
Cap. Flow %
-18%
Top 10 Hldgs %
22.96%
Holding
279
New
14
Increased
72
Reduced
169
Closed
14

Sector Composition

Rank Sector Weight
1 Technology 27.05%
2 Healthcare 26.07%
3 Industrials 15.04%
4 Consumer Discretionary 11.17%
5 Communication Services 6.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
THR
176
DELISTED
Thermon Group Holdings
THR
$2.21M 0.13%
+143,159
New +$2.35M
FMC icon
177
FMC
FMC
$1.3B
$2.1M 0.12%
19,894
-294
-1% -$31.7K
MLAB icon
178
Mesa Laboratories
MLAB
$566M
$2.1M 0.12%
14,897
+38
+0.3% +$6.93K
XYL icon
179
Xylem
XYL
$28.5B
$2.08M 0.12%
23,755
-266
-1% -$24.2K
CERS icon
180
Cerus
CERS
$492M
$2.06M 0.12%
572,362
+5,500
+1% +$26.3K
BRKR icon
181
Bruker
BRKR
$8.53B
$2.03M 0.12%
38,246
-327
-0.8% -$19.5K
SHYF
182
DELISTED
The Shyft Group
SHYF
$2.02M 0.12%
99,012
+250
+0.3% +$5.83K
SKY icon
183
Champion Homes
SKY
$5.04B
$2.02M 0.12%
38,271
-10,804
-22% -$630K
NESR
184
National Energy Services Reunited Corp
NESR
$3.55B
$2.02M 0.12%
339,519
+878
+0.3% +$5.9K
EHC icon
185
Encompass Health
EHC
$12.5B
$2M 0.12%
44,269
-11,905
-21% -$596K
EW icon
186
Edwards Lifesciences
EW
$53.3B
$2M 0.12%
24,220
-3,682
-13% -$354K
TNL icon
187
Travel + Leisure Co
TNL
$4.51B
$1.99M 0.12%
58,400
-31,281
-35% -$1.32M
USPH icon
188
US Physical Therapy
USPH
$1.23B
$1.99M 0.12%
26,213
+520
+2% +$50K
TECH icon
189
Bio-Techne
TECH
$11.2B
$1.92M 0.11%
27,032
-312
-1% -$27K
TVTX icon
190
Travere Therapeutics
TVTX
$5.81B
$1.92M 0.11%
77,837
-24,154
-24% -$624K
ESTA icon
191
Establishment Labs
ESTA
$2.24B
$1.91M 0.11%
34,946
-499
-1% -$29.8K
PUBM icon
192
PubMatic
PUBM
$772M
$1.9M 0.11%
114,295
-554
-0.5% -$10K
ZYXI
193
DELISTED
Zynex
ZYXI
$1.85M 0.11%
203,921
+137,353
+206% +$1.2M
IEX icon
194
IDEX
IEX
$17.2B
$1.81M 0.11%
9,077
-104
-1% -$21K
JNJ icon
195
Johnson & Johnson
JNJ
$630B
$1.81M 0.11%
11,102
-360
-3% -$60.9K
TTC icon
196
Toro Company
TTC
$9.37B
$1.81M 0.11%
20,957
-279
-1% -$23.9K
BMRN icon
197
BioMarin Pharmaceuticals
BMRN
$13B
$1.78M 0.1%
21,031
-28,972
-58% -$2.58M
JOUT icon
198
Johnson Outdoors
JOUT
$504M
$1.77M 0.1%
34,546
+90
+0.3% +$5.63K
KEX icon
199
Kirby Corp
KEX
$6.97B
$1.73M 0.1%
28,418
-1,131
-4% -$72.4K
CXT icon
200
Crane NXT
CXT
$2.95B
$1.73M 0.1%
56,719
-723
-1% -$23.8K

Similar funds

Rice Hall James & Associates's Q3 2022 Portfolio in Review

As of Q3 2022, Rice Hall James & Associates held 279 positions worth $1.72B, down 17% from $2.07B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Rice Hall James & Associates withdrew a net $310M in Q3 2022, closing 14 positions and reducing 169 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $7.39M position sold in full.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in TechTarget worth $8.44M.

  • Rice Hall James & Associates's largest Q3 2022 buy was TechTarget: 142,597 shares worth $8.44M.
  • Rice Hall James & Associates added most to Upland Software in Q3 2022, an estimated $3.67M increase.
  • Rice Hall James & Associates's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $26.8M.
  • Rice Hall James & Associates fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $7.39M.
  • Rice Hall James & Associates's ten largest holdings make up 23% of its $1.72B portfolio in Q3 2022.
  • Rice Hall James & Associates opened 14 new positions and closed 14 in Q3 2022.
  • Rice Hall James & Associates's portfolio value fell 17% quarter-over-quarter to $1.72B.

Based on Rice Hall James & Associates's 13F filing for Q3 2022, filed 1 Nov 2022.